Karin Havenith - Concepedia

Author

Karin Havenith

University College London ORCID

Also Known As

Havenith, K, K Havenith, K. Havenith, KARIN HAVENITH, Karin E. Havenith, Karin E.G. Havenith, Karin Havenith

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

University College London Adc Therapeutics (Switzerland)Spirogen (United Kingdom)Medical College of Wisconsin Case Western Reserve University

About

Karin Havenith is an author at University College London specializing in medicine, immunology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	620
2	Immunology	5	5	519
3	Health Sciences	1	1	53
4	Allergy	1	1	14
5	Cell Biology	1	1	17

Karin Havenith

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial Paolo F. Caimi, Weiyun Z. Ai, Juan Pablo Alderuccio, The Lancet Oncology Loncastuximab TesirineLymphoid NeoplasiaHematological MalignancyMedicineImmunology	2021	397
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma Mehdi Hamadani, John Radford, Carmelo Carlo‐Stella, Blood	2020	165
A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody–Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Brad S. Kahl, Mehdi Hamadani, John Radford, Clinical Cancer Research	2019	102
Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study Mehdi Hamadani, Graham P. Collins, Paolo F. Caimi, The Lancet Haematology Lymphoid NeoplasiaMedicineCamidanlumab TesirineImmune Checkpoint InhibitorImmunotherapy	2021	84
CD25-targeted antibody–drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity Francesca Zammarchi, Karin Havenith, François Bertelli, Journal for ImmunoTherapy of Cancer	2020	77
Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia Nitin Jain, Wendy Stock, Amer M. Zeidan, Blood Advances ImmunologyImmunotherapeuticsPharmacotherapyAnti-cd19 Antibody-drug ConjugateImmunotherapy	2020	53
Features of Macrophage Differentiation Induced by p19INK4d, a Specific Inhibitor of Cyclin D–Dependent Kinases Masashi Adachi, Martine F. Roussel, Karin Havenith, Blood	1997	49
Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study Aaron D. Goldberg, Ehab Atallah, David A. Rizzieri, Leukemia Research Hematological MalignancyOncologyAntibody-drug ConjugateHematologyImmunology	2020	38
Features of Macrophage Differentiation Induced by p19INK4d, a Specific Inhibitor of Cyclin D–Dependent Kinases Masashi Adachi, Martine F. Roussel, Karin Havenith, Blood	1997	19
ADCT-502, a novel pyrrolobenzodiazepine (PBD)-based antibody–drug conjugate (ADC) targeting low HER2-expressing solid cancers Francesca Zammarchi, Simon Chivers, David G. Williams, European Journal of Cancer Antibody–drug ConjugateDrug TargetingMedicineNovel PyrrolobenzodiazepinePharmacology	2016	17

Page 1